Reassessing Biomarkers: Guiding Second-Line Therapy in Upper GI Cancer

Experts discuss how biomarker testing results should be reassessed or expanded upon disease progression and how they guide the selection of second-line therapies or clinical trial enrollment.

EP: 1.Robert’s Journey With HER2  Upper GI Cancer

EP: 2.Frontline Treatment and Molecular Testing in Upper GI Cancer: Precision-Guided Therapy

EP: 3.Reflex Testing in Upper GI Cancer: Optimizing Molecular Insights for Timely Treatment

EP: 4.The Role of Biomarkers for Immunotherapy Selection in Upper GI Cancer

Now Viewing

EP: 5.Reassessing Biomarkers: Guiding Second-Line Therapy in Upper GI Cancer

EP: 6.Navigating Prognosis and Treatment Goals in Upper GI Cancer: A Patient- and Family-Centered Approach

EP: 7.Megan’s Journey With HER2+ Upper GI Cancer

EP: 8.Understanding PD-L1 CPS: Impact on Treatment Decisions in HER2+ Gastric Cancer

EP: 9.Trastuzumab Deruxtecan in HER2+ Gastric Cancer: Insights From DESTINY-Gastric02

EP: 10.Biomarkers and Clinical Features Guiding HER2-Directed Therapy in Upper GI Cancer

EP: 11.MSS Status and Pembrolizumab: Assessing Benefits and Considering Combinations Beyond Progression in Upper GI Cancer

EP: 12.Exploring Next-Line Options: Therapies Beyond Trastuzumab Deruxtecan in HER2+ MSS Gastric Cancer

Video content above is prompted by the following:

• How should biomarker testing results be reassessed or expanded upon disease progression, and how do they guide the selection of second-line therapies or clinical trial enrollment?

Recent Videos